New drugs will drive female contraceptives market to $8.7 billion by 2027

8 February 2019

Contraceptive market sales were estimated to be $6.3 billion across the eight leading markets (8MM: USA, France, Germany, Italy, Spain, UK, Japan and China) in 2017, which is expected to grow to $8.2 billion in 2027, at a compound annual growth rate (CAGR) of 2.7%, new research shows.

According to data and analytics company GlobalData’s report: ‘ Contraceptives: Opportunity Analysis and Forecasts to 2027’, the launch of four novel contraceptive drug candidates will drive growth of the female contraceptive market over the forecast period.

Launching products include Mithra’s (Euronext Brussels: MITRA) combined pill, Estelle (15mg estetrol (E4)/3mg drospirenone (DRSP), Evofem’s non-hormonal gel, Amphora (ethinyl estradiol ring), The Population Council’s and Antares’ transdermal gel, Nestragel, and The Population Council’s and TherapeuticsMD’s extended-release vaginal ring, Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is already approved in the US)A

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK